Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Lovro
Lovro Gotovac, Woodbridge CA
| Patent application number | Description | Published |
|---|---|---|
| 20090025189 | Cleat Holding Device - The present invention is a holding device for a rope, cable, wire and the like hereafter referred to as rope and more particularly a sliding cam rope cleat comprised of a holding device, a slideable cam member controlled by a sliding handle and two passageways therethrough for the rope member. While the sliding handle is engaged in the open position, the cam member will not be resident in the first passageway and a rope member may be freely inserted and drawn. However once the sliding handle is engaged in the clamping position, the cam member will partially obstruct the first passageway and the tapered serrated bottom of the cam member will engagingly grip and secure the inserted rope member. Subsequently, the holding device provides for a quick release of the secured rope member by returning the sliding member to its first open position thereby disengaging the tapered serrated cam member for the inserted rope member. In addition, the holding device offers a second passageway which serves as a storage receptacle for any slack in the rope member. | 01-29-2009 |
| 20100102079 | FLUID NOZZLE - This invention relates to a hand pump adapted for discharging fluid from a portable container, and particularly relates to a hand pump having a first and second valve means for discharging fluid from a portable container. The invention also relates to a method of discharging fluid from a portable container by use of a hand pump. | 04-29-2010 |
Lovro Gotovac US
| Patent application number | Description | Published |
|---|---|---|
| 20080197247 | Stand apparatus - The present invention is a stand apparatus for a display screen (such as a computer monitor or a TV) having an arcuate arm member, a base adapted to accept the arm member and allow for tilting movement of the arm member in relation to the base, and a contoured clamp member operable to engage and grip the arm member. The curvature of the clamp member matches the curvature of the arm member and prevents damage to the finish of the arm member. The clamp member is coupled with an arm screw member that is readily accessible to a user. The cross-section of the arm member prevents lateral movement of the arm member in relation to the base. The base is operable to freely swivel 360 degrees and can be readily fixed in relation to a base ring once it is in a desired position. Cabling channels are also provided within the arm member to house cables from the display screen. | 08-21-2008 |
Lovro Selic, Celje SI
| Patent application number | Description | Published |
|---|---|---|
| 20090176849 | Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives - The invention relates to a new process for the preparation of sartans 2-butyl-3-[[2′-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one is disclosed, which proceeds via novel intermediate, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]phenylboronic acid (Formula (II)) or its analogs. Compound (II) reacts with 5-(2-bromophenyl)-1-(triphenylmethyl)-1H-tetrazole (III) in the presence of catalyst, using conditions of Suzuki reaction, to give trityl irbesartan (I), whereas analogs to compound (II) may give candesartan, valsartan, telmisartan, losartan and olmesartan. | 07-09-2009 |
| 20090234139 | Novel Process - A novel process for the preparation of 1′-hydroxy-2′-substituted cyclohexyl azetidin-2-one compound of formula 2, which is important intermediate in the synthesis of trinems, is described by epoxide ring opening of (3S,4R)-3-[(1R)-1-(tert-butyldimethylsilyloxy)ethyl]-4-[(1′R,2′S,3′R)-1′,2′-epoxycyclohexan-3′-yl]azetidin-2-one of formula 1 with the nucleophile compound of formula RYH, where nucleophile may act as solvent itself if the nucleophile is in the liquid form, in a suitable solvent and in the presence of a suitable catalyst from the group of salt of trifluoromethane sulfonic acid, preferably ytterbium (III) trifluoromethanesulfonate, stannous (II) trifluoromethanesulfonate or dysprosium (III) trifluoromethanesulfonate, under a) ultrasonic irradiation or b) under microwave irradiation of the reaction mixture following by isolation and purification of the desired compound. A variant of the novel process describes ring epoxide opening of the starting compound of formula 1 with the compound of formula NH | 09-17-2009 |
| 20090240060 | PROCESS FOR THE PREPARATION OF PURE IRBESARTAN - A process for the manufacturing of a pure irbesartan comprising converting irbesartan or a protected derivative thereof into an isolated hydrohalide acid addition salt, whereupon said hydrohalide acid addition salt is converted into the irbesartan is described. | 09-24-2009 |
Lovro Selic, Ljubljana SI
| Patent application number | Description | Published |
|---|---|---|
| 20110130378 | EZETIMIBE PROCESS AND COMPOSITION - The present invention describes a process for producing ezetimibe (EZT) from a protected compound, including a step of deprotecting the 4-(p-hydroxyphenyl) protection group by catalytic hydrogenation, wherein the catalyst is used in an amount of 0.7 wt.-% or lower, relative to the weight of the compound used for the deprotection reaction. After carrying out a step of deprotection reaction, the process preferably comprises: (a) the reaction product is dissolved or extracted in ethyl acetate, and (b) the ethyl acetate solution is washed with an aqueous salt solution. The invention further describes a process for obtaining pure EZT, wherein raw EZT is dissolved in a solvent at a concentration of lower than 0.1 g/ml, and a crystallization step is carried out from this solution. These measures, respectively alone and particularly in combination contribute to attain ezetimibe (EZT) free of critical impurities described herein, and thus to use exceptionally pure ezetimibe (EZT) to be formulated into a pharmaceutical composition together with a pharmaceutically acceptable carrier or excipient. | 06-02-2011 |